Pharmaceutical Business review

Bederra completes acquisition of Diagnos

Bederra issued 15 million restricted common shares of stock for the assets of Diagnosis, which will operate as a wholly owned subsidiary of Bederra.

Graham Williams, president of Bederra, said: “The acquisition of Diagnos is the first of many medical related acquisitions planned to enhance our revenues in the coming years.”